Regional, multimodal, and opioid-sparing strategies after trauma: a review Authors: Emily Hancin, Purvi Pravinchandra Patel, Tanya Egodage Published: 2026 ABSTRACT SummaryEffective analgesia is fundamental in the management of trauma, critical care, and emergency surgical patients. However, historical reliance on opioid-based pain management strategies can be associated with adverse effects, including respiratory depression, delirium, and prolonged opioid exposure after discharge, leading to dependence. In response, multimodal analgesia strategies emphasizing non-opioid and regional techniques have become an important adjunct in trauma care pathways. This review summarizes current evidence supporting neuraxial anesthesia, peripheral and truncal nerve blocks, and non-opioid pharmacological agents as components of opioid-sparing analgesic techniques in injured and critically ill patients. Collectively, these pain management strategies support an evidence-based approach to analgesia that reduces opioid exposure and optimizes early walking and functional recovery in postoperative patients. Integration of these modalities into protocolized and perioperative pathways represents a critical step toward more effective analgesia for patients. Introduction Trauma remains a leading cause of morbidity and mortality worldwide and accounts for a substantial amount of emergency department visits, hospital admissions, and surgical interventions.1 Patients with traumatic injuries frequently experience significant pain related to their injuries, which can be exacerbated by subsequent therapeutic interventions and may persist beyond the initial hospitalization period.2 Inadequately controlled pain in trauma patients can lead to multiple complications, including venous thromboembolism, impaired respiratory effort, and delayed mobilization.3 4 Effective analgesic strategies are thus a critical component of trauma care to optimize recovery and minimize complications in this vulnerable patient population. Opioid-based analgesia has traditionally served as the foundation for pain management among trauma patients in the USA. Although effective, opioids are associated with many risks, including respiratory depression, delirium, ileus, dependence, and prolonged opioid exposure after discharge.5 6 These adverse effects can be exacerbated in trauma patients, who may have a diminished physiological ability to respond, have a prolonged postinjury course, or are older adults with multiple injuries. Opioids can hinder the recovery process in these patients by delaying walking, reducing the ability to participate in pulmonary hygiene exercises, altering gastrointestinal physiology, and compromising neurological assessments. Collectively, these features highlight the limitations of opioid-based analgesic regimens in the care of trauma patients and underscore the need for alternative methods of effective pain control. In response to these issues, multimodal analgesic strategies emphasizing non-opioid agents have become central to contemporary trauma care pathways. These approaches aim to optimize analgesia and minimize opioid-related adverse effects, particularly in vulnerable populations such as older adults, patients with traumatic brain injuries, and the critically ill. Several non-opioid pharmacological options have demonstrated efficacy across a range of traumatic and perioperative settings and are increasingly supported by guideline-based recommendations.710 This review seeks to discuss these alternative methods of pain control and describe their application in the care of the injured and critically ill patient. Neuraxial anesthesia Neuraxial and paravertebral anesthesia involve injection of medication near the spinal cord or spinal nerves, including the epidural space, subarachnoid (intrathecal) space, or paravertebral region to provide targeted pain control (table 1). These techniques require specialized expertise. Epidural anesthesia involves inserting a catheter into the epidural space with subsequent intermittent or continuous infusion of medication.11 Spinal anesthesia is a single administration of medication into the subarachnoid space, which contains cerebrospinal fluid (CSF).12 13 Paravertebral blocks are a type of regional anesthesia that targets spinal nerves adjacent to the vertebrae. Table 1Summary of neuraxial anesthesia techniquesTechniqueApproachAdvantagesDisadvantagesEpidural anesthesiaCatheter placed in the epidural space at thoracic or lumbar level (intermittent or continuous infusion)Enhanced pulmonary mechanics in rib fracturesRequires procedural expertise and ongoing monitoring, hypotension, urinary retention, lower extremity weakness, and reduced mobilityIntrathecal (spinal) analgesiaSingle injection into the subarachnoid spaceRapid onset, effective pain reliefRequires procedural expertise, time-limited effects, hypotension, respiratory depression, and pruritusParavertebral blockInjection alongside spinal nerves as they exit intervertebral foraminaReduced hypotension and motor blockade, preserves mobilityRequires procedural expertise and limited availability Summary of neuraxial anesthesia techniques Thoracic and lumbar epidurals involve delivery of a local anesthetic medication, often in combination with opioids, into the epidural space.8 11 14 Epidural analgesia primarily inhibits sympathetic innervation, thereby ameliorating abdominal surgical pain.15 Whereas thoracic epidural anesthesia provides upper abdominal analgesia, lumbar epidural anesthesia may be used for lower abdominal operations, inguinal approaches, or lower extremity procedures. Despite the fact that the lumbar approach may be preferred by the provider, studies demonstrate that the thoracic approach is preferable, given fewer complications.16 Thoracic epidurals reduce myocardial demand, whereas lumbar epidurals may worsen myocardial blood flow and oxygen delivery, portending worse outcomes for patients with significant cardiac history. Thoracic epidurals are associated with improved pulmonary function as compared to general anesthesia.1719 Thoracic epidurals are also associated with fewer postoperative gastrointestinal issues after laparotomy, with a decreased rate of ileus as compared to patients treated primarily with systemic opioid regimens. Thoracic epidurals have the potential for improved wound healing, given studies demonstrating increased wound tissue oxygenation.17 For injured patients, epidural analgesia has demonstrated improved pain control and enhanced pulmonary mechanics in patients with rib fractures as well as those undergoing thoracotomy or laparotomy.20 21 Thoracic epidural anesthesia improves postoperative morbidity and mortality in certain populations. However, its use, especially in the lumbar distribution, is associated with important limitations, including hypotension from sympathetic blockade, urinary retention, lower extremity weakness, and reduced mobility, all of which may be particularly consequential in trauma and critically ill patients.22 Epidurals must be used with caution in patients on therapeutic anticoagulation, and they should be conducted after termination of anticoagulation administration at predefined intervals.23 In addition, epidural placement and management require a trained regional anesthesia provider and ongoing monitoring, which may limit feasibility in some centers or clinical scenarios. Intrathecal (spinal) analgesia involves direct injection of an opioid, with or without a local anesthetic, into the CSF and can provide analgesia to the abdomen, but more commonly the pelvis and lower extremities.24 It has demonstrated utility in both laparotomy and laparoscopy.25 26 This technique is associated with rapid onset and potent pain relief, making it useful in select perioperative settings. However, its effects are time-limited, and like epidural techniques, administration requires specialized expertise and carries risks related to neuraxial blockade, including hypotension, pruritus, and dose-dependent respiratory depression.27 Paravertebral blocks represent an alternative regional technique in which local anesthetic is injected alongside the spinal nerves as they exit the intervertebral foramina. This approach provides unilateral segmental analgesia and may reduce some of the systemic effects associated with epidural analgesia, such as hypotension and bilateral motor blockade. Paravertebral blocks have been used effectively for thoracic and abdominal pain syndromes, including rib fractures and thoracotomy, and they can be delivered as single injections or through catheter-based techniques.28 Although still requiring procedural expertise, paravertebral blocks offer a valuable balance between effective analgesia and preservation of mobility in appropriately selected patients. Peripheral anesthesia Peripheral nerve blocks (PNBs) are highly effective adjuncts to multimodal analgesia in trauma and acute care surgery, offering substantial opioid-sparing benefits and improving pain control and facilitating early mobilization.14 29 These techniques are associated with a favorable safety profile, with reported risks of peripheral nerve injury of approximately 0.03% and local anesthetic systemic toxicity of 1.3 per 10 000 patients.30 PNBs are most commonly performed under ultrasound guidance, which enhances accuracy, efficacy, and procedural safety (figure 1).83133 Steps to conduct a peripheral nerve block. PNBs encompass both nerve plexus and distal PNBs (table 2). In the upper extremity, brachial plexus approaches, including interscalene, supraclavicular, and infraclavicular blocks, are frequently used for shoulder dislocations, proximal humerus fractures, and hand or wrist injuries.34 Compared with systemic analgesia, these techniques provide superior pain control for distal extremity injuries and are associated with improved patient comfort. Continuous brachial plexus catheter techniques have additionally been shown to extend analgesia into the postoperative period and, in some cases, may reduce pain persisting up to 30 days.34 For shoulder dislocations specifically, interscalene blocks have been associated with shorter emergency department lengths of stay compared with procedural sedation.30 35 Table 2Summary of peripheral anesthesia techniquesTechniqueApproachAnalgesic coverageUpper extremity blocksInterscalene, supraclavicular, and infraclavicularShoulder, proximal humerus, hand, and wristLower extremity blocksFascia iliaca compartment, femoral nerve, and pericapsular nerve groupHip and distal fracturesTruncal blocksSerratus anterior plane and erector spinae planeThoracic injuriesTransversus abdominis plane blocksInjection between internal oblique and transversus abdominis (T6–L1) through subcostal, lateral/mid-axillary, and posterior approachesAnterolateral abdominal wall Summary of peripheral anesthesia techniques In the lower extremity, regional analgesia plays a central role in the management of hip and more distal fractures. Techniques such as the fascia iliaca compartment block, femoral nerve block, and pericapsular nerve group block are recognized as best practice by both the American College of Surgeons and the American Academy of Orthopedic Surgeons for hip fractures.30 A large systematic review encompassing 49 randomized trials demonstrated that PNBs reduce pain with movement, decrease rates of delirium and pulmonary complications, and shorten time to mobilization.36 These benefits translate into improved functional recovery and reduced hospital length of stay, particularly with fascia iliaca-based techniques.30 37 Truncal nerve blocks have also expanded beyond their traditional indications in recent years. Serratus anterior plane blocks and erector spinae plane blocks are becoming increasingly used in thoracic trauma, particularly rib fractures. Among these, erector spinae plane blocks have demonstrated significant reductions in pain scores and improvements in inspiratory capacity, supporting their role as effective, ultrasound-guided regional options in patients with chest wall injuries.30 38 39 The transversus abdominis plane (TAP) block is a practical and effective regional analgesic technique that can be readily incorporated into multimodal pain management strategies in trauma and acute care surgery. Importantly, TAP blocks can be safely performed by surgeons in non-academic and resource-limited settings, expanding access to regional analgesia beyond specialized anesthesia services. By providing targeted somatic analgesia to the anterolateral abdominal wall, TAP blocks are particularly beneficial after laparotomy, laparoscopy, and abdominal trauma, where incisional and parietal pain are major contributors to postoperative opioid requirements.8 40 41 Anatomically, the lower thoracic and first lumbar nerves (T6–L1) that supply the abdominal wall course within the fascial plane between the internal oblique and transversus abdominis muscles. Deposition of local anesthetic within this plane results in effective blockade of somatic afferent input from the anterior abdominal wall and preserves visceral sensation.42 TAP blocks may be performed under ultrasound guidance or via direct visualization during laparotomy or laparoscopy, making them accessible to surgeons without formal regional anesthesia training or continuous anesthesia support.4345 Multiple TAP block approaches have been described, allowing the technique to be tailored to incision location and anticipated dermatomal coverage (figure 2). The subcostal approach allows for injection along the subcostal margin, from the xiphoid to the anterior iliac crest. It targets higher thoracic dermatomes (approximately T6–T10) and is particularly useful for upper abdominal incisions.42 The lateral or mid-axillary approach allows for injection in the mid-axillary line between the costal margin and iliac crest. This targets T10–L2 nerves and provides an anterior field block. The posterior approach is performed close to the quadratus lumborum, near the posterior axillary line, targeting local nerves in the T5–L1 distribution.46 Given their technical simplicity, favorable safety profile, and demonstrated opioid-sparing effects, TAP blocks represent a valuable, surgeon-driven regional analgesia option that can be seamlessly integrated into perioperative and trauma care pathways outside of academic centers.8 Variable approaches to a TAP block. TAP, transversus abdominis plane. Non-opioid analgesics Non-opioid pharmacological agents are integral components of multimodal analgesia strategies in trauma and acute care surgery. By targeting distinct pain pathways, these medications reduce opioid exposure and maintain effective analgesia. When incorporated into structured analgesia pathways, non-opioid medications reduce opioid requirements and improve pain control across perioperative, emergency, and critical care settings (table 3). Table 3Summary of non-opioid pharmacological analgesic optionsDrug agentMechanism of actionUsesRisksNon-steroidal anti-inflammatory drugsInhibit COX enzymesCan be safely used in fractures and musculoskeletal injuriesDyspepsia, bleeding, peptic ulcer disease, renal dysfunction, and conflicting evidence surrounding risk for anastomotic leakNMDA antagonists (ketamine)Inhibit glutamate-mediated excitatory neurotransmission at the NMDA receptorCan achieve comparable pain control to opioids in some populationsDelirium, dysphoria, sympathetic stimulation, and conflicting trial resultsSkeletal muscle relaxantsCentrally reduce motor neuron activityMuscle spasms, rib fractures, spinal injuries, and postoperative painSedation, dizziness, hypotension, and deliriumAntiepilepticsBind α2 subunit of presynaptic calcium channelsNeuropathic pain, hyperalgesia, and central sensitizationSedation, dizziness, gait instability, and respiratory depressionSerotonin norepinephrine reuptake inhibitors/selective serotonin reuptake inhibitorsIncrease serotonin and norepinephrineChronic neuropathic pain and musculoskeletal injuriesDelayed onset, drug interactions, and serotonin syndromeAlpha-2 adrenergic receptor agonistsInhibit norepinephrine release in locus coeruleus and dorsal hornAdditional effects of anxiolysis and sedationHypotension and bradycardiaTopical lidocaineSodium channel blockerLocal neuropathic pain and postoperative painLocal skin irritation, can cause systemic toxicity if applied over broken skinTopical capsaicinTransient receptor potential vanilloid 1 receptor agonist, depletes substance PLocalized neuropathic and musculoskeletal pain, and repeated application for sustained effectLocal skin irritationMethoxyflurane (Penthrox)Activates γ-aminobutyric acid receptors and inhibits excitatory transmission at the NMDA receptorCan be used in the prehospital or postoperative setting and useful adjunct for procedural painDizziness, headache, nausea, vomiting, hepatotoxicity, and renal toxicity in high dosesSuzetrigineBlocks NaV1.8 in sensory neuronsModerate to severe acute pain in adults, postoperative pain, and some potential in chronic and neuropathic painCYP3A-mediated drug interactions, low relative pain control compared with full-dose opioidsCYP3A, Cytochrome P450 3A subfamily; NMDA, N-methyl-D-aspartate. Summary of non-opioid pharmacological analgesic options CYP3A, Cytochrome P450 3A subfamily; NMDA, N-methyl-D-aspartate. Non-steroidal anti-inflammatory drugs Non-steroidal anti-inflammatory drugs (NSAIDs) remain a foundational component of multimodal analgesia in trauma patients, particularly for those with musculoskeletal injuries. It has historically been questioned whether NSAIDs should be used in the post-traumatic patient, given a concern for non-union of orthopedic injuries. To investigate this, the Eastern Association for the Surgery of Trauma (EAST) conducted a literature review for recommendations in a Practice Management Guideline. EAST thus conditionally recommends the use of NSAIDs in adult patients with traumatic fractures, stating that higher-level studies demonstrate no risk of non-union. Furthermore, they conditionally recommend ketorolac for adult trauma patients with fractures, also stating that studies demonstrate improved analgesia and opioid-sparing effects without association with non-union.10 Additional concerns, including renal dysfunction, peptic ulcer disease, gastrointestinal symptoms, and bleeding risk, have historically limited NSAID use in trauma populations; however, contemporary data suggest that judicious administration in carefully selected patients can provide meaningful analgesic benefit and minimize harm. Hill and colleagues conducted a retrospective cohort study of patients with blunt solid organ injury and found no increased bleeding risk with individuals who received NSAIDs.47 Within this evolving evidence base, ketorolac represents a well-studied NSAID in trauma pain management, with evidence demonstrating effective analgesia and opioid-sparing effects at lower doses, though its use does remain associated with a risk of gastrointestinal bleeding, highlighting the need for careful patient selection.48 Several trials have further demonstrated no difference in analgesic response with 15 mg of ketorolac compared with 30 mg, with one study demonstrating an increased requirement for rescue analgesics with the lower dose.49 50 However, ketorolac 30 mg is associated with higher rates of gastrointestinal bleeding, so 15 mg is recommended in the injured or postoperative patient.50 Another frequently cited concern is the potential association between ketorolac and anastomotic leak after gastrointestinal operations.51 Although early retrospective studies suggested a possible increased risk, more recent analyses and meta-analyses have produced mixed results, with several demonstrating no independent association after controlling for confounding factors.5254 Given these data, NSAIDs have been increasingly incorporated into standardized trauma and postoperative analgesia pathways. N-methyl d-aspartate antagonist (ketamine) Ketamine is an N-methyl d-aspartate (NMDA) receptor antagonist that targets central sensitization by inhibiting glutamate-mediated excitatory neurotransmission at the NMDA receptor. This mechanism is particularly important in opioid tolerance, hyperalgesia, and severe acute pain states.55 At subdissociative doses, ketamine provides effective analgesia with significant opioid-sparing effects.56 Potential complications include delirium, dysphoria, and sympathetic stimulation, highlighting the need for careful patient selection and close monitoring.57 Although intravenous ketamine has traditionally been used for sedation, recent studies have evaluated its role in pain control at lower doses than those required for sedative effects.58 In a randomized trial evaluating subdissociative ketamine infusions, Klugh and colleagues demonstrated a significant reduction in opioid exposure, including an absolute decrease of 7 morphine milligram equivalents (MME) per day, a reduction of 96 MME in total opioid use, and a 5% absolute reduction in opioid prescription rates. Although these benefits were accompanied by an increased incidence of delirium, this study highlighted the ability of ketamine to improve pain control and decrease opioid use.57 On the contrary, Carver and colleagues conducted a randomized controlled trial in severely injured trauma patients and found that adjustable-dose ketamine infusion did not significantly reduce opioid consumption or pain scores compared with placebo, leading to termination of the study for futility.39 This highlights the idea that ketamine’s efficacy may vary across patient populations and dosing strategies. Despite these conflicting data, current clinical practice guidelines from the Society of Critical Care Medicine support ketamine infusion as an adjunct for analgesia, noting the decrease in opioid use and reduction of opioid hyperalgesia.59 The recommended dose includes an initial intravenous bolus of 0.5 mg/kg followed by a continuous infusion of 1–2 μg/kg/min. Several randomized controlled intensive care unit (ICU) trials demonstrate that ketamine can achieve pain control comparable to that of opioids alone.60 61 Similarly, the American Society of Regional Anesthesia and Pain Medicine endorses perioperative ketamine use, particularly in patients who are expected to experience moderate-to-severe postoperative pain or those with pre-existing opioid tolerance.62 These recommendations should be interpreted in the context of conflicting trial results, which highlight the need for additional randomized controlled trials to better define the role of ketamine infusion in injured patients. Ketamine infusions require hemodynamic monitoring, although adverse effects include only acute dissociation, transient hypertension, and tachycardia, in contrast to the hypotension and respiratory depression commonly associated with opioids. Oral ketamine represents an evolving strategy for extended analgesia outside of continuous infusion settings. Enteral administration results in lower peak ketamine concentrations but increased production of active metabolites, including norketamine and hydroxynorketamine, which retain analgesic efficacy and produce fewer psychomimetic side effects. Pilot studies have demonstrated the safety and effectiveness of oral ketamine at doses of approximately 1 mg/kg in postoperative patients, including those undergoing limb amputation and spinal operations.63 64 More recently, its use in colorectal surgery has been associated with reduced opioid consumption without increases in adverse events or hospital length of stay, suggesting a potential role for oral ketamine in enhanced recovery and trauma care pathways.65 Enteral ketamine’s lower peak plasma levels may reduce the need for continuous hemodynamic monitoring, making its monitoring requirements similar to those used for oral oxycodone.66 Despite low-risk profiles for enteral ketamine, institutional policies guide its use and monitoring. Skeletal muscle relaxants Skeletal muscle relaxants (eg, cyclobenzaprine, methocarbamol, baclofen, and tizanidine) are primarily used to treat pain associated with muscle spasms rather than nociception itself. Most act centrally at the level of the brainstem or spinal cord to reduce tonic motor neuron activity. Baclofen (a γ-aminobutyric acid (GABA) agonist) and tizanidine (an α2 agonist) reduce excitatory neurotransmission within the spinal cord, whereas agents such as methocarbamol and cyclobenzaprine exert more generalized sedative and antispasmodic effects.67 These medications can be useful adjuncts for rib fractures, spinal injuries, and postoperative abdominal or thoracic wall pain. Their use, however, is limited by potential adverse effects, including sedation, dizziness, hypotension, and delirium, particularly in older or critically ill patients.8 68 Antiepileptics Gabapentin and pregabalin are structural analogs of GABA that do not act directly on GABA receptors. Instead, they bind to an α2 subunit of presynaptic voltage-gated calcium channels, reducing calcium influx and subsequent release of excitatory neurotransmitters such as glutamate and substance P.69 These agents are particularly effective for neuropathic pain, hyperalgesia, and central sensitization and are frequently incorporated into multimodal perioperative analgesia pathways. Their opioid-sparing effects are well documented; however, adverse effects, including sedation, dizziness, gait instability, and respiratory depression, especially when combined with opioids, necessitate cautious dosing in trauma and ICU populations.8 40 70 Serotonin norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors Serotonin norepinephrine reuptake inhibitors (SNRIs; eg, duloxetine and venlafaxine) and selective serotonin reuptake inhibitors (SSRIs; eg, fluoxetine, citalopram, and sertraline) exert analgesic effects primarily through modulation of descending inhibitory pain pathways in the central nervous system. By increasing synaptic levels of serotonin and norepinephrine, SNRIs enhance endogenous spinal cord mechanisms of pain inhibition. SNRIs have demonstrated efficacy in chronic neuropathic pain, musculoskeletal pain, and centralized pain syndromes, whereas SSRIs have more modest and less consistent analgesic effects.71 These agents are not typically used for the management of acute pain, but they may be beneficial in subacute or chronic trauma-related pain, especially in patients with comorbid depression or anxiety. Limitations include delayed onset of analgesia, drug–drug interactions, and risks of serotonin syndrome when combined with other serotonergic agents.8 72 Alpha-2 adrenergic receptor agonists Alpha-2 agonists such as clonidine and dexmedetomidine provide analgesia through inhibition of norepinephrine release in the locus coeruleus and dorsal horn of the spinal cord, thereby reducing sympathetic tone and nociceptive transmission.73 These agents are particularly useful as adjuncts in opioid-sparing regimens, regional anesthesia, and ICU sedation strategies. Their analgesic benefit is accompanied by anxiolysis and sedation, but hypotension and bradycardia can limit their use in hemodynamically unstable trauma patients.73 74 Topical lidocaine and capsaicin Although many non-opioid adjuncts are available as intravenous or oral medications, several topical options can provide local pain relief. Lidocaine patches are used frequently in postoperative patients to relieve nerve pain.75 Lidocaine acts as a sodium channel blocker that stabilizes neuronal membranes and reduces nociceptive signaling. Clinical studies have shown that lidocaine patches can lower postoperative pain scores and reduce opioid consumption without significant systemic effects.7678 Topical capsaicin, although less commonly used, has demonstrated efficacy in the treatment of localized neuropathic pain. It functions as a transient receptor potential vanilloid 1 (TRPV1) receptor agonist, depleting substance P and reducing pain signal transmission.79 Capsaicin has shown benefit in chronic conditions such as osteoarthritis, and evidence also supports reductions in postoperative pain scores and opioid requirements.80 Repeated application produces sustained analgesic effects, which further support its use in pain management.81 The most common side effect of these topical adjuncts is local skin irritation, with a rare risk for systemic toxicity with the use of lidocaine when applied over broken skin.82 83 These safety profiles make them particularly useful in patient populations where systemic side effects are a concern. Emerging analgesics: methoxyflurane (Penthrox) and suzetrigine Methoxyflurane is a volatile anesthetic agent with analgesic properties at subanesthetic doses, which can persist into the postoperative period, thereby reducing the need for opioids.84 Its exact mechanism of action is unknown, but it is known to activate the GABA receptor and attenuate excitatory transmission mediated by NMDA receptors.85 86 It is self-administered via inhalation and takes effect within 2–5 min, which makes it a useful adjunct for pain associated with short procedures such as fracture reduction and wound dressing changes.84 In 2005, the US Food and Drug Administration (FDA) discontinued the use of methoxyflurane for anesthesia due to reports of fatal nephrotoxicity and hepatotoxicity associated with high anesthetic doses.87 However, emergency medical services in Australia, Canada, and Europe have adopted a lower-dose inhaler version of methoxyflurane (Penthrox, Medical Developments International Limited, Victoria, Australia), which has been shown to significantly reduce pain in patients with minimal serious adverse effects.84 88 89 A recent comparative study showed that methoxyflurane demonstrated superior analgesic efficacy and a faster onset of action than intramuscular tramadol, though a higher incidence of minor adverse effects was observed.90 The most common side effects include dizziness, nausea, and vomiting, whereas kidney and liver toxicity appear to be primarily associated with high-dose exposure.91 More recently, the FDA lifted the clinical hold on methoxyflurane, enabling renewed investigation into its potential role in non-opioid regimens in the USA.92 Suzetrigine selectively inhibits the voltage-gated sodium channel NaV1.8, a key component of peripheral nociceptive signaling that is expressed in primary sensory neurons but not within the central nervous system. This peripheral selectivity limits centrally mediated adverse effects such as sedation and respiratory depression.93 Clinical trials have demonstrated efficacy in postoperative pain, including abdominoplasty, where suzetrigine significantly reduced pain compared with placebo.94 The agent received FDA approval in early 2025 for the treatment of moderate-to-severe acute pain in adults.95 Beyond its approved use in acute pain, suzetrigine has shown analgesic effects in preclinical models of neuropathic pain and in early clinical studies of neuropathic conditions.9698 However, evidence in chronic pain populations is limited, and its role in long-term pain management has yet to be established. Although suzetrigine provides effective non-opioid analgesia relative to placebo, its effects are modest compared with full-dose opioids, long-term outcomes data remain limited, and, because it is metabolized by cytochrome P450 3A subfamily (CYP3A) enzymes, co-administration with strong CYP3A inhibitors or inducers can alter its drug levels and limit its use in certain patient populations.99 Non-pharmacological approaches Although many non-opioid medications can be used in the treatment of post-traumatic and postoperative pain, non-pharmacological options can provide meaningful adjunctive benefit. Physical therapy is frequently prescribed, especially after trauma or surgical intervention, to support recovery and promote mobility. Its efficacy largely depends on patient participation and adherence to exercises outside of formal sessions, but numerous studies demonstrate its value in pain relief in both acute and chronic settings. Acupuncture has demonstrated analgesic effects in postinjury and postoperative arenas, likely through the modulation of abnormal neurological function, influencing intracellular signaling pathways, or increasing endogenous opioid peptides in the brain.100102 Pet or animal-assisted therapy can reduce pain perception, anxiety, and stress, particularly in hospitalized or critically ill patients.103 Biofeedback, a technique that trains patients to control normally involuntary physiological processes, has shown efficacy as a complementary therapy for chronic pain and headache disorders; however, its use for acute pain remains limited.104 105 Similarly, meditation and mindfulness-based stress reduction have been shown to reduce acute and chronic pain, improve coping, and decrease anxiety and depression.106108 Hypnosis may modulate patients’ response to pain in some contexts, but its effectiveness is less consistently demonstrated; for example, a recent study of critically ill cardiac surgery patients found no significant differences in anxiety and pain scores in those who participated in hypnosis versus controls.109 Although the effects of these complementary non-pharmacological therapies can vary, clinicians can use them in appropriate settings to support individualized pain management strategies. Didactic education Numerous courses are available to enhance proficiency in regional anesthesia. For example, the American College of Surgeons has a Safe Pain Control initiative and has offered courses such as ‘Safe Pain Control and Regional Anesthesia for the Practicing General Surgeon’ in the past.110 Surgeons who are interested in incorporating regional anesthetic techniques into their own practice can pursue formal training through such courses, attend workshops led by experienced practitioners, and seek mentorship from colleagues who are proficient in these skills. Additionally, providers can assess the feasibility for application of these techniques within their own institutions by identifying select patient populations appropriate for regional blocks, establishing streamlined protocols in conjunction with anesthesiology colleagues, and gradually integrating these approaches into trauma surgical care pathways. These strategies allow for safe and efficient implementation of these pain management adjuncts. Summary Neuraxial anesthesia, PNBs, and non-opioid analgesics play an increasingly central role in trauma and acute care surgery, enabling effective pain control and reducing opioid exposure and its associated risks. Each offers a distinct mechanism of action and complementary benefits. Incorporation of these agents into protocolized, patient-centered analgesia strategies aligns with contemporary guideline recommendations and represents a critical step toward safer, more effective pain management in trauma and surgical critical care populations.